Cargando…

Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

BACKGROUND: The identification of a BRCA1 or BRCA2 mutation in familial breast cancer kindreds allows genetic testing of at risk relatives. However, considerable controversy exists regarding the cancer risks in women who test positive for the family mutation. METHODS: We reviewed 385 unrelated famil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, D Gareth, Shenton, Andrew, Woodward, Emma, Lalloo, Fiona, Howell, Anthony, Maher, Eamonn R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447846/ https://www.ncbi.nlm.nih.gov/pubmed/18513387 http://dx.doi.org/10.1186/1471-2407-8-155

Ejemplares similares

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers
por: Evans, DG, et al.
Publicado: (2017)

Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
por: Gareth Evans, D, et al.
Publicado: (2004)

BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
por: Kitson, Sarah J., et al.
Publicado: (2020)

Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer
por: Hyder, Zerin, et al.
Publicado: (2020)

MSH2 is the very young onset ovarian cancer predisposition gene, not BRCA1
por: Flaum, Nicola, et al.
Publicado: (2023)

Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
por: Gaudet, Mia M., et al.
Publicado: (2010)

Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
por: Gaudet, Mia M., et al.
Publicado: (2010)

Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
por: Gaudet, Mia M., et al.
Publicado: (2010)

Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?
por: Prosperi, Mattia CF, et al.
Publicado: (2014)

Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability
por: Evans, D. Gareth, et al.
Publicado: (2021)

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
por: Nguyen-Dumont, Tu, et al.
Publicado: (2020)

Metaplastic breast cancer and BRCA1: first strong evidence of a link
por: Evans, D. Gareth R, et al.
Publicado: (2023)

Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients
por: Torres, D., et al.
Publicado: (2017)

Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America
por: Herzog, Josef S., et al.
Publicado: (2021)

Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels
por: Crosbie, Emma J., et al.
Publicado: (2020)

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
por: Evans, D. Gareth, et al.
Publicado: (2019)

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
por: Evans, D G R, et al.
Publicado: (2010)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases
Publicado: (2000)

Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer
por: Kemp, Zoe, et al.
Publicado: (2019)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

Fanconi Anaemia, Childhood Cancer and the BRCA Genes
por: Woodward, Emma R., et al.
Publicado: (2021)

The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology
por: Lalloo, Fiona, et al.
Publicado: (1999)

Understanding of BRCA VUS genetic results by breast cancer specialists
por: Eccles, B. K., et al.
Publicado: (2015)

Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population
por: Geredeli, Caglayan, et al.
Publicado: (2019)

Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation
por: Mansfield, Carol A., et al.
Publicado: (2020)

Genetic testing for BRCA1 and BRCA2 mutations - ready for implementation?
por: Weber, BL
Publicado: (2000)

Genetic Variation of the Brca1 and Brca2 Genes in Macedonian Patients
por: Maleva, I, et al.
Publicado: (2012)

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
por: Kote-Jarai, Z, et al.
Publicado: (2011)

"Strong interaction" for particle physics laboratories
Publicado: (2003)

BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway
por: Heramb, Cecilie, et al.
Publicado: (2018)

High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
por: Møller, Pål, et al.
Publicado: (2010)

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
por: Girardi, Fabio, et al.
Publicado: (2018)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
por: Coignard, Juliette, et al.
Publicado: (2021)

BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management
por: Girolimetti, Giulia, et al.
Publicado: (2014)

Genetic instability in the RAD51 and BRCA1 regions in breast cancer
por: Nowacka-Zawisza, Maria, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_8kk6i62dcd20er39pl88ns1nqo